Position for site-specific attachment of a DOTA chelator to synthetic affibody molecules has a different influence on the targeting properties of 68Ga-Compared to 111in-labeled conjugates

Molecular Imaging

Volumn 13, Issue 10, 2014, Pages

  Honarvar, Hadis ^b   Strand, Joanna ^b   Perols, Anna ^b   Orlova, Anna ^b   Selvaraju, Ram Kumar ^b   Karlström, Amelie Eriksson ^b   Tolmachev, Vladimir ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; CHELATION; MAMMALS; MOLECULAR IMAGING; MOLECULES; PARTICLE BEAMS; POSITRONS; PROBES; PROTEINS; SCAFFOLDS (BIOLOGY); SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TUMORS;

AFFIBODY MOLECULES; BEST POSITION; BIODISTRIBUTIONS; IMAGING PROBE; IMAGING PROPERTIES; POSITRON EMISSION TOMOGRAPHY (PET); RADIOLABELING; SCAFFOLD PROTEIN;

POSITRON EMISSION TOMOGRAPHY;

1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; AFFIBODY Z(HER2-S1); CHELATING AGENT; GALLIUM; HYBRID PROTEIN; INDIUM; SINGLE HETEROCYCLIC RINGS;

ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; COMPARATIVE STUDY; FEMALE; HUMAN; ISOTOPE LABELING; MOUSE; OVARY TUMOR; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; FEMALE; GALLIUM RADIOISOTOPES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MICE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECOMBINANT FUSION PROTEINS;

EID: 84918563830     PISSN: 15353508     EISSN: 15360121     Source Type: Journal    
DOI: 10.2310/7290.2014.00034     Document Type: Article

References (54)

1. Mankoff DA. Molecular imaging to select cancer therapy and evaluate treatment response. J Nucl Med Mol Imaging 2009;53: 181-92.
2. Tolmachev V, Stone-Elander S, Orlova A. Radiolabelled receptor tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010;11:992-1000, doi:10.1016/S1470-2045(10)70088-7.
3. Kelloff GJ, Krohn KA, Larson SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 2005;11:7967-85, doi:10.1158/1078-0432.CCR-05-1302.
4. Van Dongen GA, Visser GW, Lub-de Hooge MN, et al. Immuno-PET: a navigator in monoclonal antibody development and applications.Oncologist 2007;12:1379-89, doi:10.1634/theoncologist.12-12-1379.
5. Tolmachev V, Rosik D, Wållberg H, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 2010;37: 613-22, doi:10.1007/s00259-009-1283-x.
6. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med 2005;46:1940-5.
7. Miao Z, Levi J, Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 2011;41:1037-47, doi:10.1007/s00726-010-0503-9.
8. Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 2007;10:167-75.
9. Löfblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:2670-80, doi:10.1016/j.febslet.2010.04.014.
10. Nygren PA. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008;275:2668-76, doi:10.1111/j.1742-4658.2008.06438.x.
11. Orlova A, Magnusson M, Eriksson TL, et al. Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res 2006;66:4339-48, doi:10.1158/0008-5472.CAN-05-3521.
12. Malm M, Kronqvist N, Lindberg H, et al. Inhibiting HER3-mediated tumor cell growth with Affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One 2013;8:e62791, doi:10.1371/journal.pone.0062791.
13. Lindborg M, Cortez E, Hoiden-Guthenberg I, et al. Engineered high affinity Affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J Mol Biol 2011;407:298-315, doi: 10.1016/j.jmb.2011.01.033.
14. Tolmachev V, Malmberg J, Hofstrom C, et al. Imaging of insulin like growth factor type 1 receptor in prostate cancer xenografts using the Affibody molecule 111In-DOTA-ZIGF1R:4551. J Nucl Med 2012;53:90-7, doi:10.2967/jnumed.111.090829.
15. Ahlgren S, Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 2010;11:581-9, doi: 10.2174/138920110792246609.
16. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008;14:2999-3019, doi:10.2174/ 138161208786404290.
17. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;2:1-13, doi:10.1159/000055396.
18. Carlsson J. EGFR-family expression and implications for targeted radionuclide therapy. In: Stigbrand T, Carlsson J, Adams G, editors. Targeted radionuclide tumor therapy: biological aspects. London: Springer; 2008. p. 25-58.
19. Arteaga CL, Sliwkowski MX, Kent Osborne C, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012;9:16-32, doi:10.1038/nrclinonc.2011.177.
20. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97, doi:10.1016/S0140-6736 (10)61121-X.
21. Barginear MF, John V, Budman DR. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med 2012;18:1473-9, doi:10.2119/molmed.2012.00302.
22. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45, doi:10.1200/JCO.2006.09.2775.
23. Baum RP, Prasad V, Müller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled Affibody molecules. J Nucl Med 2010;51:892-7, doi:10.2967/jnumed.109.073239.
24. Sörensen J, Sandberg D, Carlsson J, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 Affibody molecule. J Nucl Med 2014;55:730-5, doi:10.2967/jnumed.113.131243.
25. Kiesewetter DO, Krämer-Marek G, Ma Y, et al. Radiolabeling of HER2 specific Affibody molecule with F-18. J Fluor Chem 2008; 129:799-805, doi:10.1016/j.jfluchem.2008.06.021.
26. Tolmachev V, Friedman M, Sandström M, et al. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry. J Nucl Med 2009; 50:274-83, doi:10.2967/jnumed.108.055525.
27. Ahlgren S,Wållberg H, Tran TA, et al. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant Affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 2009;50:11-2, doi:10.2967/jnumed.108.056929.
28. Cheng Z, De Jesus OP, Kramer DJ, et al. 64Cu-labeled Affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 2010;12:316-24, doi:10.1007/s11307-009-0256-6.
29. Kramer-Marek G, Shenoy N, Seidel J, et al. 68Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging 2011;38:1967-76, doi:10.1007/s00259-011-1810-4.
30. Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem 2008;19:235-43, doi:10.1021/bc700307y.
31. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic Affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007;67:2178-86, doi:10.1158/0008-5472.CAN-06-2887.
32. Engfeldt T, Orlova A, Tran T, et al. Imaging of HER2-expressing tumors using a synthetic Affibody molecule containing the 99mTcchelating mercaptoacetyl-glycyl-glycylglycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 2007;34:722-33, doi:10.1007/s00259-006-0266-4.
33. Engfeldt T, Tran T, Orlova A, et al. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 2007;34:1843-53, doi:10.1007/s00259-007-0474-6.
34. Decristoforo C, Mather SJ. 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution. Nucl Med Biol 1999;26:389-96, doi:10.1016/ S0969-8051(98)00118-8.
35. Antunes P, Ginj M, Walter MA, et al. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. Bioconjug Chem 2007;18:84-92, doi:10.1021/bc0601673.
36. Froidevaux S, Eberle AN, Christe M, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002;98: 930-7, doi:10.1002/ijc.10295.
37. Tran T, Engfeldt T, Orlova A, et al. In vivo evaluation of cysteinebased chelators for attachment of 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem 2007;18:549-58, doi:10.1021/bc060291m.
38. Malmberg J, Perols A, Varasteh Z, et al. Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2012;39:481-92, doi:10.1007/s00259-011-1992-9.
39. Perols A, Honarvar H, Strand J, et al. Influence of DOTA chelator position on biodistribution and targeting properties of 111Inlabeled synthetic anti-HER2 Affibody molecules. Bioconjug Chem 2012;23:1661-70, doi:10.1021/bc3002369.
40. Wållberg H, Ahlgren S, Widström C, et al. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-ZHER2:2395(-Cys) Affibody molecule for targeting of HER2-expressing tumors.Mol Imaging Biol 2010;12:54-62, doi:10.1007/s11307-009-0238-8.
41. Tolmachev V, Velikyan I, Sandström M, et al. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 2010;37:1356-67, doi:10.1007/s00259-009-1367-7.
42. Honarvar H, Jokilaakso N, Andersson K, et al. Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for in vivo molecular imaging. Nucl Med Biol 2013;40:378-86, doi:10.1016/j.nucmedbio.2012.12.009.
43. Strand J, Honarvar H, Perols A, et al. Influence of macrocylic chelators on the targeting properties of 68Ga-labeled synthetic Affibody molecules: comparison with 111In-labeled counterparts. PLoS One 2013;8:e70028, doi:10.1371/journal.pone.0070028.
44. Wållberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 2008; 23:435-42, doi:10.1089/cbr.2008.0464.
45. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8:2861-71, doi:10.1158/1535-7163.MCT-09-0195.
46. Vegt E, M de Jong, Wetzels JFM, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010;51:1049-58, doi:10.2967/jnumed.110.075101.
47. Hosseinimehr SJ, Tolmachev V, Orlova A. Factors influencing liver uptake of radiolabelled targeting protein and peptides: consideration for design of targeting conjugate peptide. Drug Discov Today 2012;17:1224-32, doi:10.1016/j.drudis.2012.07.002.
48. Antunes P, Ginj M, Zhang H, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labeled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-93, doi:10.1007/s00259-006-0317-x.
49. Tolmachev V, Orlova A. Influence of labelling methods on biodistribution and imaging properties of radiolabelled peptides for visualisation of molecular therapeutic targets. Curr Med Chem 2010;17:2636-55, doi:10.2174/092986710791859397.
50. Tolmachev V, Stone Elander S. Radiolabelled proteins for positron emission tomography: pros and cons of labeling methods. Biochim Biophys Acta 2010;1800:487-510.
51. Heppeler A, Froidevaux S, Mäcke HR, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor mediated internal radiotherapy. Chem Eur J 1999;5:1974-81, doi:10.1002/(SICI)1521-3765(19990702)5:7〈1974::AID-CHEM1974〉3.0.CO;2-X.
52. Cummings MC, Simpson PT, Reid LE, et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J Pathol 2013;232:23-31, doi:10.1002/path.4288.
53. Altai M, Strand J, Rosik D, et al. Influence of nuclides and chelators on imaging using Affibody molecules: comparative evaluation of recombinant Affibody molecules site-specifically labeled with 68Ga and 111In via maleimido derivatives of DOTA and NODAGA. Bioconjug Chem 2013;24:1102-9, doi:10.1021/bc300678y.
54. Lubberink M, Tolmachev V, Widström C, et al. 110mIn-DTPA-DPhe1-octreotide for imaging of neuroendocrine tumors with PET. J Nucl Med 2002;43:1391-7.